TrialA Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Trial details
- Registry ID
- NCT07142811
- Phase
- Phase 2
Drug research
Bulevirtide
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as BJT-778; Hepcludex
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811 | VIR | Phase 2 | Active not recruiting | 2026-11Estimated |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550 | VIR | Phase 3 | Active not recruiting | 2026-12Estimated |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideNCT07454837 | MIRM | Phase 2, Phase 3 | Recruiting | 2027-08-31Estimated |
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
Trial details
- Registry ID
- NCT07128550
- Phase
- Phase 3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Trial details
- Registry ID
- NCT07454837
- Phase
- Phase 2, Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |